Regeneron Highlights Health Risks of Weight-Loss Drugs
George Yancopoulos, the co-founder and chief scientific officer of Regeneron Pharmaceuticals Inc (NASDAQ: REGN), has raised important health concerns regarding the increasingly popular class of GLP-1 weight-loss medications. His apprehension mainly revolves around the potential for rapid muscle loss, which can negate the overall benefits of these drugs.
Concerns Over Muscle Loss
Yancopoulos cautioned that if not adequately managed, the side effects of GLP-1 treatments could result in patients experiencing “more harm than good.” Emerging clinical studies reveal alarming statistics, indicating that individuals using these medications, such as Novo Nordisk A/S’ (NYSE: NVO) Ozempic and Wegovy, suffer greater muscle loss relative to those who incorporate traditional weight loss methods, including diet and exercise.
Adherence Issues with GLP-1 Treatments
Analyzing U.S. pharmacy claims data, research has found that only 25% of patients prescribed Wegovy and Ozempic maintain their treatment regimen after two years. This low adherence raises further alarms about the sustainability and effectiveness of these weight-loss solutions.
Impact on Body Composition
Yancopoulos highlighted another pressing concern: patients who stop using GLP-1 medications often regain weight, but with a higher fat-to-muscle ratio. He described this outcome as “adding insult to injury,” emphasizing the long-term potential for negative changes in body composition among users of these drugs.
Research Directions: Muscle Preservation
As these issues mount, Regeneron is actively investigating methods to preserve muscle mass while patients lose weight. The company has initiated a Phase 2 trial involving trevogrumab, which works by blocking myostatin, a hormone known to inhibit muscle growth. This innovative approach is being studied in conjunction with Wegovy (semaglutide), with topline results anticipated in the latter half of 2025.
Promising Early Results
Regeneron’s previous studies, specifically a Phase 1 trial evaluating garetosmab (an anti-activin A compound) and trevogrumab, revealed promising results. These studies demonstrated that when combined, these therapies not only increased lean mass significantly but also reduced fat mass in healthy participants.
The Competitive Landscape
In the growing field of obesity treatments, Eli Lilly and Co (NYSE: LLY) has made significant strides by acquiring Versanis Bio for up to $1.925 billion. This acquisition enhances its portfolio of obesity medications. Eli Lilly claims that its bimagrumab can effectively reduce fat mass while simultaneously preserving muscle mass in individuals dealing with obesity and related complications.
Future Directions for Regeneron
Looking ahead, Yancopoulos has hinted that Regeneron may explore entering the GLP-1 market with its formulations, albeit with caution. He expressed skepticism about whether GLP-1 medications can truly address the complexities of metabolic diseases.
Stock Performance Update
Price Action: At the latest review, REGN stocks experienced a slight dip, down by 0.23% to $1,010.51, reflecting broader market trends.
Frequently Asked Questions
What are GLP-1 medications?
GLP-1 medications are a class of drugs used for weight loss and diabetes management, designed to mimic the effects of the glucagon-like peptide hormone.
Why is muscle preservation important during weight loss?
Poor muscle preservation can lead to negatively affecting metabolism, physical strength, and overall health after weight loss, which is why maintaining muscle mass is critical.
What is Regeneron doing about muscle loss in weight-loss medications?
Regeneron is conducting research to develop treatments that promote muscle growth while patients lose weight with traditional medications.
What are the expected results from Regeneron's Phase 2 trial?
The Phase 2 trial for trevogrumab, aimed at preserving muscle during weight loss, is expected to yield topline results in the latter half of 2025.
How are other companies responding to these health risks?
Companies like Eli Lilly are also developing new treatments that aim to reduce fat while preserving muscle mass to address the shortcomings of existing GLP-1 medications.
